Comprehensive treatment approach for esophageal cancer using precision radiotherapy
Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy
This study is testing a new way to personalize radiotherapy for patients with advanced esophageal cancer to see if it can improve their treatment outcomes and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | ChineseAMS |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05543057 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with locally advanced esophageal cancer (EC) undergoing radiotherapy. It aims to classify patients into appropriate therapeutic groups based on clinical and pathological factors, utilizing multiple liquid biopsy technologies and radiomics to construct prediction models for prognosis, therapeutic effect, and toxicity. The goal is to optimize treatment regimens and improve patient outcomes and quality of life through precision radiotherapy. By addressing the limitations of existing imaging methods, this study seeks to enhance clinical decision-making in the treatment of esophageal cancer.
Who should consider this trial
Good fit: Ideal candidates include individuals with pathology-proven esophageal cancer and an ECOG performance status of 3 or lower.
Not a fit: Patients who are pregnant, lactating, or deemed inappropriate by researchers will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment plans for patients with esophageal cancer.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving treatment outcomes through personalized medicine in oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathology proved esophageal cancer * ECOG PS ≤3 * Signed Informed consent Exclusion Criteria: * Pregnant and lactating women * Others that researchers consider inappropriate
Where this trial is running
Beijing, Beijing
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) — Beijing, Beijing, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.